Servier, announced the acquisition of Pixuvri from CTI BioPharma. Pixuvri is a treatment for adult patients with multiply relapsed or...
The European Commission has given conditional marketing authorization for Pixuvri (pixantrone), from Cell Therapeutics, as monotherapy for the treatment of...
NICE (The National Institute for Health and Care Excellence) has finally recommended Pixuvri (pixantrone)) from Cell Therapeutics for the treatment...
Servier Laboratories and CTI BioPharma Corp.,jointly announced that they have entered into an exclusive license and collaboration agreement to develop...
NICE has issued draft guidance not recommending the use of Pixuvri (pixantrone), from Cell Therapeutics, for an aggressive form of...
New results have been released from the Phase III trial of Pixuvri (pixantrone dimaleate), from Cell Therapeutics, for patients with...
The FDA has accepted the resubmission of Pixuvri(pixantrone dimaleate) from Cell Therapeutics as a single-agent treatment of patients with relapsed...
NICE has issued second draft guidance on Pixuvri (pixantrone), from Cell Therapeutics, as a treatment of adult patients with multiply...
Servier announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued...
Results from sub-set analyses of data from the Phase III EXTEND (PIX301) clinical trial of Pixuvri (pixantrone), from Cell Therapeutics,...